Published: 2016-06-30

Primary aldosteronism as an endocrinological challenge – old doubts and new diagnostic possibilities

Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poland
Department of Anatomy, Poznan University of Medical Sciences, Poland
Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poland
primary aldosteronism adrenal tumor aldosterone producing adenoma bilateral adrenal hyperplasia adrenal CT adrenal venous sampling

Abstract

Hypertension constitutes a common clinical problem worldwide. In fact, a systematic increase in its detection is predicted in the following years, with early detection, accurate diagnosis and effective treatment of hypertension being a priority. The most common endocrinological cause of hypertension is primary aldosteronism. What is more, elevated aldosterone levels cause a deterioration in blood pressure normalization, diabetes, and significantly increase cardiovascular risk. There are two distinct causes of primary aldosteronism – aldosterone producing adenoma (APA), as well as bilateral adrenal hyperplasia (BAH) and proper differentiation between APA and BAH has clinical implications. In the case of the former adrenalectomy is advised, whereas the latter is followed by introduction of proper pharmacotherapy with aldosterone antagonists (spironolactone, eplerenone).

Downloads

Download data is not yet available.

References

  1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J., Global burden of hypertension: analysis of worldwide data, Lancet. 2005 Jan 15–21;365(9455):217–23.
  2. Beevers G., Lip G.Y.H., O’Brien E. The pathophysiology of hypertension. BMJ 2001;322: 912––916
  3. Makris A, Seferou M, Papadopoulos DP, Resistant hypertension workup and approach to treatment, Int J Hypertens. 2010 Dec 26;2011:598694.
  4. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM; American Heart Association Professional Education Committee.
  5. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Circulation. 2008 Jun 24;117(25):e510–26.
  6. Young WF Jr., Primary aldosteronism: A common and curable form of hypertension., Cardiol Rev. 1999 Jul-Aug;7(4):207–14
  7. Schwartz GL, Screening for adrenal-endocrine hypertension: overview of accuracy and cost-effectiveness, Endocrinol Metab Clin North Am. 2011 Jun;40(2):279–94, vii.
  8. Faselis C, Doumas M, Papademetriou V., Common secondary causes of resistant hypertension and rational for treatment., Int J Hypertens. 2011 Mar 2;2011:236239.
  9. Sarwar MS, Islam MS, Al Baker SM, Hasnat A, Resistant hypertension: underlying causes and treatment, Drug Res (Stuttg). 2013 May;63(5):217–23.
  10. Rossi GP., Prevalence and diagnosis of primary aldosteronism, Curr Hypertens Rep. 2010 Oct;12(5):342–8.
  11. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr., Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents, J Clin Endocrinol Metab. 2004 Mar;89(3):1045–50.
  12. Kaplan NM, Is there an unrecognized epidemic of primary aldosteronism?,Hypertension. 2007 Sep;50(3):454–8; discussion 454–8.
  13. Stiefel P, Aparicio R, Carneado J, Pamies E, Villar J., The current epidemic of primary aldosteronism: causes and consequences, J Hypertens. 2004 Oct;22(10):2040–2.
  14. Krishnan PH, MacDonald T., The current epidemic of primary aldosteronism: causes and consequences, J Hypertens. 2004 Oct;22(10):2039–40
  15. Galati SJ, Hopkins SM, Cheesman KC, Zhuk RA, Levine AC., Primary aldosteronism: emerging trends, Trends Endocrinol Metab. 2013 Sep;24(9):421–30.
  16. Conn JW., Primary aldosteronism: a new clinical syndrome. J Lab Clin Med. 1955;43: 3–17
  17. Lityński M., Nadciśnienie tętnicze wywołane guzami korowo-nadnerczowymi, Pol Tyg Lek. 1953;8: 204–208
  18. Young WF Jr., Minireview: primary aldosteronism--changing concepts in diagnosis and treatment, Endocrinology. 2003 Jun;144(6):2208–13
  19. Takase K et al, Adrenal venous sampling revisited – Crucial role in the management of primary aldosteronism Patients, ECR 2012
  20. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA, Role for adrenal venous sampling in primary aldosteronism,, Surgery. 2004 Dec;136(6):1227–35.
  21. Lim V, Guo Q, Grant CS, Thompson GB, Richards ML, Farley DR, Young WF Jr, Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism, J Clin Endocrinol Metab. 2014 Aug;99(8):2712–9.
  22. Arlt W.: A detour guide to the Endocrine Society Clinical Practice Guideline on case detection, diagnosis and treatment of patients with primary aldosteronism, Eur. J. Endocrinol., 2010;162: 435–438
  23. Shiroto H, Ando H, Ebitani I, Hara M, Numazawa K, Kawamura S, Sasaki H., Normotensive primary aldosteronism, Am J Med. 1980 Oct;69(4):603–6.
  24. Kono T, Ikeda F, Oseko F, Imura H, Tanimura H., Normotensive primary aldosteronism: report of a case, J Clin Endocrinol Metab. 1981 May;52(5):1009–13.
  25. Vantyghem MC, Ronci N, Provost F, Ghulam A, Lefebvre J, Jeunemaitre X, Tabarin A., Aldosterone-producing adenoma without hypertension: a report of two cases, Eur J Endocrinol. 1999 Sep;141(3):279–85.
  26. Médeau V, Moreau F, Trinquart L, Clemessy M, Wémeau JL, Vantyghem MC, Plouin PF, Reznik Y., Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases, Clin Endocrinol (Oxf). 2008 Jul;69(1):20–8.
  27. Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, Conlin PR., Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia., J Hum Hypertens. 2006 Feb;20(2):129–36.
  28. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators., A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients, J Am Coll Cardiol. 2006 Dec 5;48(11):2293–300.
  29. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89: 1045–1050.
  30. Gordon RD, Stowasser M, Primary aldosteronism: the case for screening, Nat Clin Pract Nephrol. 2007 Nov;3(11):582–3.
  31. Ganguly A., Prevalence of primary aldosteronism in unselected hypertensive populations: screening and definitive diagnosis., J Clin Endocrinol Metab. 2001;86: 4002–4004.
  32. Kaplan NM., Primary aldosteronism: A contrarian view, Rev Endocr Metab Disord. 2011 Mar;12(1):49–52
  33. Kaplan NM, Primary aldosteronism: evidence against a second epidemic, J Hypertens. 2012 Oct;30(10):1899–902.
  34. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A., A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology, J Clin Endocrinol Metab. 2000 Feb;85(2):637–44
  35. Barzon L, Scaroni C, Sonino N, Fallo F, Gregianin M, Macri C, Boscaro M., Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates, J Clin Endocrinol Metab. 1998 Jan;83(1):55–62
  36. Funder J, Carey R, Fardella C, Gomez-Sanchez C, Mantero F, Stowasser M, Young W, Montori VM, Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline, Eur J Endocrinol. 2009 Sep 30.
  37. Fommei E, Ghione S, Ripoli A, Maffei S, Di Cecco P, Iervasi A, Turchi S., The ovarian cycle as a factor of variability in the laboratory screening for primary aldosteronism in women, J Hum Hypertens. 2009 Feb;23(2):130–5.
  38. Pizzolo F, Raffaelli R, Memmo A, Chiecchi L, Pavan C, Guarini P, Guidi GC, Franchi M, Corrocher R, Olivieri O., Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism, J Hypertens. 2010 Jan;28(1):135–42.
  39. Ahmed AH, Gordon RD et al, Are women more at risk of false-positive primary aldosteronism screening and unnecessary suppression testing than men?, J Clin Endocrinol Metab. 2011 Feb;96(2):E340–6.
  40. Weiner ID., Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism, Semin Nephrol. 2013 May;33(3):265–76.
  41. Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, Bidlingmaier M, Seissler J, Endres S; Participants of the German Conn's Registry., Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn's Registry, Horm Metab Res. 2010 Jun;42(6):435–9
  42. Hanslik G, Wallaschofski H, Dietz A, Riester A, Reincke M, Allolio B, Lang K, Quack I, Rump LC, Willenberg HS, Beuschlein F, Quinkler M, Hannemann A; participants of the German Conn's Registry., Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry, Eur J Endocrinol. 2015 Nov;173(5):665–75.
  43. Chen W, Li F, He C, Zhu Y, Tan W., Elevated prevalence of abnormal glucose metabolism in patients with primary aldosteronism: a meta-analysis, Ir J Med Sci. 2014 Jun;183(2):283–91.
  44. Sechi LA, Di Fabio A, Bazzocchi M, Uzzau A, Catena C., Intrarenal hemodynamics in primary aldosteronism before and after treatment, J Clin Endocrinol Metab. 2009 Apr;94(4):1191–7.
  45. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F; PAPY Study Participants, Renal damage in primary aldosteronism: results of the PAPY Study, Hypertension. 2006 Aug;48(2):232–8.
  46. Fallo F, Della Mea P, Sonino N, Bertello C, Ermani M, Vettor R, Veglio F, Mulatero P., Adiponectin and insulin sensitivity in primary aldosteronism, Am J Hypertens. 2007 Aug;20(8):855–61.
  47. Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, Fardella CE., A possible association between primary aldosteronism and a lower beta-cell function, J Hypertens. 2007 Oct;25(10):2125–30.
  48. Fischer E, Adolf C, Pallauf A, Then C, Bidlingmaier M, Beuschlein F, Seissler J, Reincke M., Aldosterone excess impairs first phase insulin secretion in primary aldosteronism, J Clin Endocrinol Metab. 2013 Jun;98(6):2513–20.
  49. Muiesan ML, Salvetti M, Paini A, Agabiti-Rosei C, Monteduro C, Galbassini G, Belotti E, Aggiusti C, Rizzoni D, Castellano M, Agabiti-Rosei E., Inappropriate left ventricular mass in patients with primary aldosteronism, Hypertension. 2008 Sep;52(3):529–34.
  50. Iacobellis G, Petramala L, Cotesta D, Pergolini M, Zinnamosca L, Cianci R, De Toma G, Sciomer S, Letizia C., Adipokines and cardiometabolic profile in primary hyperaldosteronism, J Clin Endocrinol Metab. 2010 May;95(5):2391–8.
  51. Karagiannis A, Treatment of primary aldosteronism: Where are we now?, Rev Endocr Metab Disord. 2011 Mar;12(1):15–20.
  52. Kotlyar E, Vita JA, Winter MR, Awtry EH, Siwik DA, Keaney JF Jr, Sawyer DB, Cupples LA, Colucci WS, Sam F., The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure, J Card Fail. 2006 Mar;12(2):122–7.
  53. Silvestre J.S., Robert V., Heymes C. Aupetit-Faisant B., Mouas C., Moalic J.M., Swynghedauw B., Delcayre C., Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J. Biol. Chem., 1998;273: 4883–4891
  54. Takeda Y., Yoneda T., Demura M., Miyamori I., Mabuchi H.: Cardiac aldosterone production in genetically hypertensive rats. Hypertension, 2000;36: 495–500
  55. Christ M., Wehling M.: Rapid actions of aldosterone: lymphocytes, vascular smooth muscle and endothelial cells. Steroids, 1999;64: 35–41
  56. Wildling L., Hinterdorfer P., Kusche-Vihrog K., Treffner Y., Oberleithner H.: Aldosterone receptor sites on plasma membrane of human vascular endothelium detected by a mechanical nanosensor. Pflugers Arch., 2009;458: 223–230
  57. Christ M., Douwes K., Eisen C., Bechtner G., Theisen K., Wehling M.: Rapid effects of aldosterone on sodium transport in vascular smooth muscle cells. Hypertension, 1995;25: 117–123
  58. Leite-Dellova D.C., Oliveira-Souza M., Malnic G., Mello-Aires M.: Genomic and nongenomic dose-dependent biphasic effect of aldosterone on Na+/H+ exchanger in proximal S3 segment: role of cytosolic calcium., Am. J. Physiol. Renal Physiol., 2008;295: F1342–F1352
  59. Rossol-Haseroth K, Zhou Q, Braun S, Boldyreff B, Falkenstein E, Wehling M, Lösel RM., Mineralocorticoid receptor antagonists do not block rapid ERK activation by aldosterone, Biochem Biophys Res Commun. 2004 May 21;318(1):281–8.
  60. Gromotowicz A, Osmólska U, Mantur M, Szoka P, Zakrzeska A, Szemraj J, Chabielska E., Prothrombotic aldosterone action--a new side of the hormone], Postepy Hig Med Dosw (Online). 2010 Oct 18;64:471–81.
  61. Marzolla V, Armani A, Feraco A, De Martino MU, Fabbri A, Rosano G, Caprio M., Mineralocorticoid receptor in adipocytes and macrophages: a promising target to fight metabolic syndrome, Steroids. 2014 Dec;91:46–53.
  62. Luther JM., Aldosterone in vascular and metabolic dysfunction, Curr Opin Nephrol Hypertens. 2015 Nov 14.
  63. Zennaro MC, Caprio M, Feve B., Mineralocorticoid receptors in the metabolic syndrome, Trends Endocrinol Metab. 2009 Nov;20(9):444–51.
  64. Funder JW, Primary Aldosteronism: New Answers, New Questions, Horm Metab Res. 2015 Nov 20.
  65. Pelliccia F, Rosano G, Patti G, Volterrani M, Greco C, Gaudio C., Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension, Int J Cardiol. 2015 Dec 1;200:8–11.
  66. Parthasarathy HK, Ménard J, White WB, Young WF Jr, Williams GH, Williams B, Ruilope LM, McInnes GT, Connell JM, MacDonald TM, A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism, J Hypertens. 2011 May;29(5):980–90.
  67. Karagiannis A, Tziomalos K, Papageorgiou A, Kakafika AI, Pagourelias ED, Anagnostis P, Athyros VG, Mikhailidis DP, Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism, Expert Opin Pharmacother. 2008 Mar;9(4):509–15.
  68. Späth M, Korovkin S, Antke C, Anlauf M, Willenberg HS, Aldosterone- and cortisol-co-secreting adrenal tumors: the lost subtype of primary aldosteronism, Eur J Endocrinol. 2011 Apr;164(4):447–55.
  69. Willenberg HS, Späth M, Maser-Gluth C, Engers R, Anlauf M, Dekomien G, Schott M, Schinner S, Cupisti K, Scherbaum WA., Sporadic solitary aldosterone- and cortisol-co-secreting adenomas: endocrine, histological and genetic findings in a subtype of primary aldosteronism, Hypertens Res. 2010 May;33(5):467–72.
  70. Fujimoto K, Honjo S, Tatsuoka H, Hamamoto Y, Kawasaki Y, Matsuoka A, Ikeda H, Wada Y, Sasano H, Koshiyama H, Primary aldosteronism associated with subclinical Cushing syndrome, J Endocrinol Invest. 2013 Sep;36(8):564–7.
  71. Hiraishi K, Yoshimoto T, Tsuchiya K, Minami I, Doi M, Izumiyama H, Sasano H, Hirata Y.,Clinicopathological features of primary aldosteronism associated with subclinical Cushing's syndrome, Endocr J. 2011;58(7):543–51.
  72. Omura M, Saito J, Matsuzawa Y, Nishikawa T., Supper-selective ACTH-stimulated adrenal vein sampling is necessary for detecting precisely functional state of various lesions in unilateral and bilateral adrenal disorders, inducing primary aldosteronism with subclinical Cushing's syndrome, Endocr J. 2011;58(10):919–20.
  73. Markou A, Sertedaki A, Kaltsas G, Androulakis II, Marakaki C, Pappa T, Gouli A, Papanastasiou L, Fountoulakis S, Zacharoulis A, Karavidas A, Ragkou D, Charmandari E, Chrousos GP, Piaditis GP., Stress-induced Aldosterone Hyper-Secretion in a Substantial Subset of Patients With Essential Hypertension, J Clin Endocrinol Metab. 2015 Aug;100(8):2857–64.
  74. Yen RF, Wu VC, Liu KL, Cheng MF, Wu YW, Chueh SC, Lin WC, Wu KD, Tzen KY, Lu CC; TAIPAI Study Group, 131I-6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results, Nucl Med. 2009 Oct;50(10):1631–7.
  75. Spyridonidis TJ, Apostolopoulos DJ. Is there a role for Nuclear Medicine in diagnosis and management of patients with primary aldosteronism? Hell J Nucl Med. 2013 May-Aug;16(2):134–9.
  76. Lombardi CP, Raffaelli M, De Crea C, Rufini V, Treglia G, Bellantone R. Noninvasive adrenal imaging in hyperaldosteronism: is it accurate for correctly identifying patients who should be selected for surgery? Langenbecks Arch Surg. 2007;392:623–628
  77. Nomura K, Kusakabe K, Maki M, Ito Y, Aiba M, Demura H., Iodomethylnorcholesterol uptake in an aldosteronoma shown by dexamethasone-suppression scintigraphy: relationship to adenoma size and functional activity, J Clin Endocrinol Metab. 1990 Oct;71(4):825–30.
  78. Goh BK, Tan YH, Chang KT, Eng PH, Yip SK, Cheng CW., Primary hyperaldosteronism secondary to unilateral adrenal hyperplasia: an unusual cause of surgically correctable hypertension. A review of 30 cases., World J Surg. 2007 Jan;31(1):72–9.
  79. Tomaschitz A, Ritz E, Pieske B, Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease, Cardiovasc Res. 2012 Apr 1;94(1):10–9.
  80. Tomaschitz A, Pilz S., Interplay between sodium and calcium regulatory hormones: a clinically relevant research field, Hypertension. 2014 Feb;63(2):212–4.
  81. Zhang LX, Gu WJ, Li YJ et al., PTH Is a Promising Auxiliary Index for the Clinical Diagnosis of Aldosterone-Producing Adenoma., Am J Hypertens. 2015 Aug 24.

How to Cite

1.
Cyrańska-Chyrek E, Grzymisławska M, Ruchała M. Primary aldosteronism as an endocrinological challenge – old doubts and new diagnostic possibilities. JMS [Internet]. 2016Jun.30 [cited 2020Aug.5];85(2):138-45. Available from: https://jms.ump.edu.pl/index.php/JMS/article/view/104